Wang, W. et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269,1588-1590

Department of Microbiology, University of Virginia, Charlottesville 22908, USA.
Science (Impact Factor: 33.61). 10/1995; 269(5230):1588-90.
Source: PubMed


H-Y is a transplantation antigen that can lead to rejection of male organ and bone marrow grafts by female recipients, even if the donor and recipient match at the major histocompatibility locus of humans, the HLA (human leukocyte antigen) locus. However, the origin and function of H-Y antigens has eluded researchers for 40 years. One human H-Y antigen presented by HLA-B7 was identified as an 11-residue peptide derived from SMCY, an evolutionarily conserved protein encoded on the Y chromosome. The protein from the homologous gene on the X chromosome, SMCX, differs by two amino acid residues in the same region. The identification of H-Y may aid in transplantation prognosis, prenatal diagnosis, and fertilization strategies.

Download full-text


Available from: Nicholas E Sherman,
  • Source
    • "could be reactivated ex vivo from the peripheral blood before and after AP1903 infusion, three of the four patients receiving AP1903 had disease relapse, compared to only one of six patients who were not so treated, raising the concern that elimination of alloreactive cells would hamper GVL (Zhou et al., 2014), because of the potential co-expression of minor histocompatibility antigens on hematopoietic and non-hematopoietic tissues (de Bueger et al., 1992; Wang et al., 1995; Meadows et al., 1997; Vogt et al., 2000). The relative contribution of alloreactive cells, as compared with TAAs specific T cells is not difficult to quantify, however since most TAAs are aberrantly expressed self-proteins resulting in T cells with low-affinity TCR, it is possible that the alloreactive component is more determinant for GvL. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adoptive T-cell therapy can involve donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation, the administration of tumor infiltrating lymphocyte (TILs) expanded ex-vivo, or more recently the use of T cell receptor (TCR) or chimeric antigen receptor (CAR) redirected T cells. However cellular therapies can pose significant risks, including graft-versus-host-disease and other on and off-target effects, and therefore strategies need to be implemented to permanently reverse any sign of toxicity. A suicide gene is a genetically encoded molecule that allows selective destruction of adoptively transferred cells. Suicide gene addition to cellular therapeutic products can lead to selective ablation of gene-modified cells, preventing collateral damage to contiguous cells and/or tissues. The ‘ideal’ suicide gene would ensure the safety of gene modified cellular applications by granting irreversible elimination of ‘all’ and ‘only’ the cells responsible for the unwanted toxicity. This review presents the suicide gene safety systems reported to date, with a focus on the state-of-the-art and potential applications regarding two of the most extensively validated suicide genes, including the clinical setting: herpes-simplex-thymidine-kinase (HSV-TK) and inducible-caspase-9 (iCasp9).
    Frontiers in Pharmacology 10/2014; 5(524). DOI:10.3389/fphar.2014.00254 · 3.80 Impact Factor
  • Source
    • "The evidence presently available suggests that JARID1D contributes to rejection of male tissues by female transplant recipients.99 There is limited research on the association between JARID1D and cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The human AT-rich interaction domain (ARID) family contains seven subfamilies and 15 members characterized by having an ARID. Members of the ARID family have the ability to regulate transcription and are involved in cell differentiation and proliferation. Accumulating evidence suggests that ARID family members are involved in cancer-related signaling pathways, highly mutated or differentially expressed in tumor tissues, and act as predictive factors for cancer prognosis or therapeutic outcome. Here we review the molecular biology and clinical studies concerned with the role played by the ARID family in cancer. This may contribute to our understanding of the initiation and progression of cancer from a novel point of view, as well as providing potential targets for cancer therapy.
    OncoTargets and Therapy 02/2014; 7:315-324. DOI:10.2147/OTT.S57023 · 2.31 Impact Factor
  • Source
    • ", but until a few years ago only two mHA had been identified: the male-specific H–Y transplantation antigen, derived from a gene located on the short arm of the Y chromosome [13] and the HA-1 antigen, an HLA-A2-restricted mHA [14]. The initiating event in GVHD is the recognition of target antigens on host cells by donor-derived immunocompetent cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Graft-versus host disease (GVHD) complicating allogeneic hematopoeitic stem cell transplantation (HSCT) is often attributed to mismatching of minor histocompatibility antigens (mHags), which are poorly defined in humans. CD31 is a candidate human mHag relevant to acute GVHD (aGVHD), but reports disagree about its level of significance. Therefore, we examined the impact of CD31-matching on the outcome of HSCT in different hematological and immunological diseases. About 60 patients receiving HSC from their respective HLA-ABCDR and DQ-identical sibling were studied. DNA was used to study the CD31 allele polymorphism at the codon 125 (LL, LV or VV) in the patient-donor pairs using the principle of allele-specific PCR amplification. Four primer were used; two primers (forward and reverse) for the L allele and another two for the V allele. The CD31 identity was tested for correlation with HSCT outcome measures of aGVHD, chronic GVHD, and relapse. The gene frequency of CD31 alleles (LL, VV and LV) was 28.3, 20 and 51.7%, respectively. CD31 identity was found in 31 pairs (51.7%) versus 29 pairs (48.3%) for nonidentity. The CD31 noncompatibility showed statistical non-significant relation with aGVHD (G 0-I, and G II-IV) and chronic GVHD (De-novo and chronic on acute) (p = 0.59, p = 0.62, p = 036 and p = 0.83, respectively). The CD31 nonidentity had statistical significant relation with aGVHD versus no aGVHD (p = 0.008 and OR = 4.46). The CD31 nonidentity showed statistical significant relation with aGVHD (II-IV) versus no aGVHD (p = 0.012 and OR = 7.14) and also, aGVHD (0-I) versus the no aGVHD (p = 0.03, OR = 3.13, respectively). A statistical significant relation was found between CD31 nonidentity in patient-donor pairs and relapse (p = 0.014 and OR = 4.21). In conclusion, the donor-recipient CD31 nonidentity is a significant risk factor for aGVHD and relapse in HLA-identical sibling.
    Hematology (Amsterdam, Netherlands) 09/2006; 11(4):227-34. DOI:10.1080/10245330600954189 · 1.25 Impact Factor
Show more